Clinical Trials to Treat Adult Metastatic Brain Tumors

Trials 1-25 of 102
1 2 3 4 5 Next >

  • Genetic Testing in Guiding Treatment for Patients with Brain Metastases

    This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK or PI3K. Medications that target these genes such as abemaciclib, GDC-0084, and entrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor treatment for each mutation.
    Location: 355 locations

  • A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases

    This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. This trial aims to find out which approach is more effective in shrinking and controlling brain metastases from melanoma.
    Location: 250 locations

  • Testing Sacituzumab Govitecan Therapy in Patients with HER2-Negative Breast Cancer and Brain Metastases

    This phase II trial studies the effect of sacituzumab govitecan in treating patients with HER2-negative breast cancer that has spread to the brain (brain metastases). Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as Trop-2 receptors, and delivers govitecan to kill them. Giving sacituzumab govitecan may shrink the cancer in the brain and / or extend the time until the cancer gets worse.
    Location: 103 locations

  • Single Fraction Stereotactic Radiosurgery or Three to Five Fraction Stereotactic Radiosurgery in Treating Patients with Brain Metastasis That Has Been Removed By Surgery

    This phase III trial studies how well single fraction stereotactic radiosurgery works compared with fractionated stereotactic radiosurgery in treating patients with cancer that has spread to the brain from other parts of the body (brain metastases) and has been removed by surgery (resected). Single fraction stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Fractionated stereotactic radiosurgery delivers multiple, smaller doses of radiation therapy over time. This study may help doctors find out if fractionated stereotactic radiosurgery is better or worse than the usual approach with single fraction stereotactic radiosurgery.
    Location: 192 locations

  • Stereotactic Radiosurgery or Hippocampus Avoidance Whole-Brain Radiation Therapy with Memantine in Treating Patients with 5-15 Brain Metastases

    This phase III trial studies stereotactic radiosurgery to see how well it works compared to hippocampus avoidance whole-brain radiation therapy with memantine in treating patients with 5-15 brain tumors that have spread from other places in the body. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Hippocampus avoidance whole-brain radiation therapy delivers radiation to the entire brain except for the hippocampus. The hippocampus is a brain structure that is important for memory. Hippocampus avoidance during whole-brain radiation therapy decreases the amount of radiation that is delivered to this area. Memantine is often given with whole brain radiation therapy and may decrease the risk of cognitive side effects after radiation therapy to the brain. It is not yet known whether stereotactic radiosurgery or whole-brain radiation therapy works better in treating patients with 5-15 brain metastases.
    Location: 52 locations

  • An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis

    This is a multicenter, randomized open-label Phase 2 study to assess the safety, efficacy and pharmacokinetic (PK) of 2 dosing regimens of encorafenib + binimetinib combination in patients with BRAFV600-mutant melanoma with brain metastasis. Approximately 100 patients will be enrolled, including 9 patients in a Safety Lead-in of the high-dose treatment arm. After a Screening Period, treatment will be administered in 28-day cycles and will continue until disease progression, unacceptable toxicity, withdrawal of consent, start of subsequent anticancer therapy, death.
    Location: 21 locations

  • Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients with Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain after Earlier Stereotactic Radiosurgery

    This phase III trial compares the effect of adding whole brain radiotherapy with hippocampal avoidance and memantine to stereotactic radiosurgery versus stereotactic radiosurgery alone in treating patients with cancer that has spread to the brain and come back in other areas of the brain after earlier stereotactic radiosurgery. Hippocampus avoidance during whole-brain radiation therapy decreases the amount of radiation that is delivered to the hippocampus, which is a brain structure that is important for memory. The medicine memantine is also often given with whole brain radiation therapy because it may decrease the risk of side effects of radiation on neurocognitive function (including thinking and memory). Stereotactic radiosurgery delivers a high dose of radiation only to the small areas of cancer in the brain and avoids the surrounding normal brain tissue. Adding whole brain radiotherapy with hippocampal avoidance and memantine to stereotactic radiosurgery may be effective in reducing the size of the cancer or keeping the cancer the same size when it has spread to the brain and / or come back in other areas of the brain following stereotactic radiosurgery.
    Location: 15 locations

  • Neratinib, Capecitabine, and Trastuzumab Emtansine in Treating Patients with HER2-Positive Breast Cancer That Has Spread to the Brain

    This phase II trial studies how well neratinib, capecitabine, and trastuzumab emtansine work in treating patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer that has spread to the brain. Neratinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab emtansine (T-DM1) is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called DM1. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers DM1 to kill them. Giving neratinib, capecitabine, and trastuzumab emtansine together may be an effective treatment for breast cancer.
    Location: 14 locations

  • Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fileds (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

    The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patients, following stereotactic radiosurgery (SRS) for 1-10 brain metastases, treated with NovoTTF-100M compared to supportive treatment alone. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.
    Location: 11 locations

  • Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

    The primary objective of the study is to evaluate the efficacy of osimertinib plus ramucirumab versus osimertinib alone using progression free survival (PFS). Events associated with PFS include: disease progression per RECIST 1.1 and death due to any cause. A total of 150 patients will be enrolled and randomized in a 2:1 fashion (osimertinib plus ramucirumab vs. osimertinib) to the two treatment arms according to the following stratification factors: types of epidermal growth factor receptor (EGFR) mutations and presence of brain metastasis.
    Location: 9 locations

  • GDC-0084 and Radiation Therapy for the Treatment of Solid Tumor Brain Metastases or Leptomeningeal Metastases with PI3K Pathway Mutations

    This phase I trial studies the side effects of GDC-0084 and radiation therapy to the brain in treating patients with PI3K pathway-mutated solid tumors that have spread to the brain and / or membranes lining the brain and spinal cord (brain and / or leptomeninges metastases). When a cancer has a PI3K pathway mutation, it sends signals to other cells in the body to encourage rapid growth, leading to the spread of cancer. PI3K mutations are common in many types of cancer, and they cause radiation therapy to be less effective. GDC-0084 reduces the activity of PI3K-related signaling. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving GDC-0084 with whole or partial brain radiation therapy may be an effective treatment for solid tumors brain metastases or leptomeningeal metastases.
    Location: 7 locations

  • Cs131 Brachytherapy for the Treatment of Recurrent Brain Metastases

    This phase II trial studies the effect of cesium (Cs)-131 brachytherapy in treating patients with cancer that has spread to the brain from other places in the body (brain metastases) and that has come back (recurrent). Cs-131 brachytherapy involves placing small radioactive seeds (Cs-131 seeds) near the area(s) of the brain where the cancer is being removed. These seeds are permanent, and they temporarily give off radiation to kill any cancer cells that may grow after surgery. Cs-131 brachytherapy may help prevent brain tumors from growing back after surgery.
    Location: 6 locations

  • Hepatic Impairment Study for Lorlatinib in Cancer Patients

    This is a phase 1 study in advanced cancer patients with varied hepatic fucntions to evaluate the potential effect of hepatic impairment on pharmacokinetics and safety of lorlatinib and provide dose recommendation for patients with hepatic impairment if possible.
    Location: 6 locations

  • A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

    This study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients. This study will test safety, tolerability and PK (how the drug is absorbed, distributed and eliminated) of ascending doses of AZD1390 in combination with distinct regimens of radiation therapy
    Location: 6 locations

  • Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients with Brain Metastases

    This phase I trial studies the side effects and best dose of ropidoxuridine when given together with whole brain radiation therapy in treating patients with cancer that has spread to the brain (brain metastases). Ropidoxuridine may help whole brain radiation therapy work better by making cancer cells more sensitive to the radiation therapy.
    Location: 8 locations

  • Whole-Brain Radiotherapy or Stereotactic Radiosurgery in Treating Patients with 5-20 Metastatic Malignant Tumors in the Brain

    This phase III trial studies how well whole-brain radiotherapy or stereotactic radiosurgery works in treating patients with 5-20 malignant tumors that have spread to the brain from other parts of the body. Whole-brain radiotherapy delivers radiation to the entire brain Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. It is not yet known whether whole-brain radiotherapy or stereotactic radiosurgery works better in treating patients with 5-20 malignant tumors in the brain.
    Location: 5 locations

  • Stereotactic Radiosurgery in Treating Patients with Small Cell Cancer and 1-10 Brain Metastases

    This phase II trial studies how well stereotactic radiosurgery works in treating patients with small cell cancer and 1-10 tumors that have spread to the brain from other parts of the body (brain metastases). Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue.
    Location: 5 locations

  • Frameless Fractionated Stereotactic Radiation in Treating Patients with Brain Metastases

    This phase II trial studies the safety and efficacy of frameless fractionated stereotactic radiation therapy for brain metastases. Frameless fractionated stereotactic radiosurgery is a specialized radiation therapy that delivers 3 to 5, high dose fractions of radiation directly to the brain lesions while sparing normal tissues.
    Location: 4 locations

  • Testing the Safety of M6620 (VX-970) When Given with Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases from Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors

    This phase I trial studies the side effects and best dose of berzosertib (M6620 [VX-970]) when given together with whole brain radiation therapy in treating patients with non-small cell lung cancer, small cell lung cancer, or neuroendocrine tumors that have spread from the original (primary) tumor to the brain (brain metastases). Berzosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving berzosertib together with radiation therapy may work better compared to standard of care treatment, including brain surgery and radiation therapy, in treating patients with non-small cell lung cancer, small cell lung cancer, or neuroendocrine tumors.
    Location: 5 locations

  • Stereotactic Radiosurgery with Abemaciclib, Ribociclib, or Palbociclib in Treating Patients with Hormone Receptor Positive Breast Cancer with Brain Metastases

    This phase I trial studies the side effects of stereotactic radiosurgery with abemaciclib, ribociclib, or palbociclib in treating patients with hormone receptor positive breast cancer that has spread to the brain (brain metasteses). Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Abemaciclib, ribociclib, and palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving abemaciclib, ribociclib, or palbociclib concurrently with stereotactic radiosurgery may reduce the side effects and / or increase the response to each of the therapies.
    Location: 3 locations

  • Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients with Incurable Esophageal and Gastroesophageal Junction Cancers

    This phase I trial investigates the side effects and best dose of adavosertib and how well it works when given in combination with radiation therapy in treating patients with esophageal or gastroesophageal junction cancer for which no treatment is currently available (incurable). Adavosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving adavosertib together with radiation therapy kill more tumor cells than radiation therapy alone in treating patients with esophageal and gastroesophageal junction cancer.
    Location: 3 locations

  • Infliximab or Corticosteroids for the Treatment of Ipilimumab Colitis

    This phase II trial studies the effect of infliximab or corticosteroids (methylprednisolone and prednisone or prednisone alone) in treating patients with inflammation of the intestines (colitis) caused by taking ipilimumab. Infliximab is a type of drug that targets a protein called TNF-alpha. This protein is responsible for regulating the inflammatory response in the body. In diseases such as colitis, there is too much of the TNF-alpha protein which causes certain parts of the body to become inflamed. The excess TNF-alpha protein is causing inflammation in the intestines, resulting in colitis. Infliximab is thought to inhibit (stop) the TNF-alpha protein from working correctly which results in the prevention of the inflammation in the intestines causing colitis. Both methylprednisolone and prednisone are corticosteroids. Corticosteroids are anti-inflammatory drugs, and it is believed that they help with the inflammation that causes colitis. Giving infliximab or corticosteroids may reduce inflammation and help fight against colitis caused by ipilimumab.
    Location: 3 locations

  • Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

    This phase I / Ib trial studies the side effects and best dose of CB-839 HCl when given together with sapanisertib in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced). CB-839 HCl and sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 3 locations

  • A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer

    This phase I / II trial studies the side effects and how well copanlisib works when given together with fulvestrant in treating patients with estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer that has spread to other places in the body (advanced) and progressing after prior treatment. HER2 and ER are two types of proteins called receptors that can affect the growth of breast cancer cells. Additionally, investigators hope to learn from this study if tumor genetic information is important for predicting whether this type of breast cancer will respond to fulvestrant and copanlisib. Copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells. Giving copanlisib and fulvestrant may work better in treating patients with ER+ and HER2- breast cancer compared to fulvestrant alone.
    Location: 3 locations

  • Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients with Operative Metastatic Brain Tumors

    This phase III trial studies the side effects and how well stereotactic radiosurgery (SRS) works before or after surgery in patients with tumors that has spread to the brain or that can be removed by surgery. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue.
    Location: 3 locations


1 2 3 4 5 Next >